What to expect at ESC Congress 2023

This year the European Society of Cardiology (ESC) 2023 Congress is being held in Amsterdam, The Netherlands from August 25 – 28 both onsite and online. The international cardiology community will gather to learn about cutting edge science, new guidelines and important developments in cardiovascular research. Hereby we provide an overview of what to expect at the ESC Congress 2023.

There will be 30 hot line presentations presented over the 4 day congress. Topics range anywhere from HFpEF subgroups to OCT vs angiography or IVUS trials, as well as multivessel immediate versus staged revascularization in STEMI.

Hereby are the headlines of the 9 Hot Line sessions.

August 25^th, Hot Line 1 Session:

STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity

NOAH-AFNET 6: Oral anticoagulation in patients with atrial high rate episodes

COP-AF – Colchicine for the prevention of perioperative atrial fibrillation after major thoracic surgery

August 26^th, Hot Line 2 Session:

Qiliqiangxin in patients with heart failure and reduced ejection fraction – the QUEST study

BUDAPEST CRT Upgrade: Cardiac resynchronisation therapy upgrade in heart failure with right ventricular pacing – a multicentre, randomised, controlled trial

HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency

Effects of FCM on recurrent HF hospitalizations: an individual participant data meta-analysis

August 26^th, Hot Line 3 Session:

FIRE trial: Physiology-Guided Complete PCI in Older MI Patients

ECLS-SHOCK – venoarterial membrane oxygenation in cardiogenic shock

STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention

August 27^th, Hot Line 4 Session:

ILUMIEN IV: OCT Versus Angiography

OCT-guided or angiography-guided PCI in complex bifurcation lesions. The OCTOBER trial

OCTIVUS: OCT- vs. IVUS-Guided PCI

OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis

August 27^th, Hot Line 5 Session:

ATTRibute-CM: acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy

ARREST trial: Expedited transfer to a cardiac arrest center for OHCA

ADVENT: Pulsed Field Ablation vs Thermal Ablation (RF/Cryo) for Paroxysmal AF

August 27^th, Hot Line 6 Session:

MULTISTARS AMI: Multivessel immediate versus staged revascularization in STEMI

CASTLE-HTx: Catheter Ablation versus Medical Therapy to Treat Atrial Fibrillation in End-stage Heart Failure

The FRAIL-AF randomized controlled trial

August 28^th, Hot Line 7 Session:

Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial

ARAMIS – Anakinra versus Placebo in Acute Myocarditis

DANPACE II – Reducing atrial pacing in Sinus Node Disease

August 28^th, Hot Line 8 Session:

RED-CVD: Improving early diagnosis of cardiovascular disease in patients with type 2 diabetes and COPD

NITRATE-CIN – Inorganic nitrate to prevent CIN after angiography for ACS

DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure

PUSH-AHF: Natriuresis guided therapy in acute heart failure

August 28^th, Hot Line 9 Session:

RIGHT: Prolongation of anticoagulation after Primary PCI

ONCO DVT Study; Optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer study

Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19

What else can we expect at ESC Congress 2023?

Further to the state-of-the-art research being presented, we can expect some ESC guideline updates. This includes updates to the management of endocarditis, cardiovascular disease in diabetic patients, cardiomyopathies, acute coronary syndrome as well as a 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.

For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.